Skip to main content
Clinical Trials/JPRN-jRCTs031180399
JPRN-jRCTs031180399
Recruiting
Phase 2

Single agent graft-versus-host disease prophylaxis with post-transplant cyclophosphamide for stem cell transplantation: a phase II study - SAP-P2

Sakaguchi Hirotoshi0 sites30 target enrollmentStarted: March 20, 2019Last updated:

Overview

Phase
Phase 2
Status
Recruiting
Sponsor
Sakaguchi Hirotoshi
Enrollment
30

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
ot applicable to < 20age old (—)
Sex
All

Inclusion Criteria

  • 1\) Diagnosed as acute leukemia (acute lymphoblastic leukemia/acute myeloblastic leukemia), or lymphoma
  • 2\) First or second remission, and planned to have stem cell transplantation
  • 3\) Donor for transplantation is one of the follows;
  • a. HLA 6/6 (A, B, DR) matched related donor
  • b. HLA 5/6 (A, B, DR) matched related donor
  • c. HLA 6/6 (A, B, DR) matched unrelated donor
  • 4\) Age at transplantation \<20 years
  • 5\) ECOG Performance status: 0\-2
  • 6\) Sufficient organ function, as follows;
  • a. T\-Bil \<\= 1\.5 mg/dl

Exclusion Criteria

  • 1\. Prior allogeneic stem cell transplantation
  • 2\. Effusion with grade 2 or worse at CTCAE ver 4\.0
  • 3\. Uncontrolled infection
  • 4\. Severe psychological disorders
  • 5\. Pregnant or suspected pregnancy
  • 6\. Not eligible for this study at the discretion of the investigator.

Investigators

Sponsor
Sakaguchi Hirotoshi

Similar Trials

Recruiting
Not Applicable
Single agent graft-versus-host disease prophylaxis with post-transplant cyclophosphamide for stem cell transplantation: a phase II study (SAP-P2)Acute leukemia
JPRN-UMIN000021375ational Center for Child Health and Development30
Active, not recruiting
Phase 1
Prevention of graft-against-host disease in patients treated with allogeneic stem cell transplantation: Possible role of extracorporeal photophoresisGraft-versus-host disease (GVHD), both acute and chronic untill one year after allogeneic stam cell transplatationTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2017-000614-39-NOOSLO UNIVERSITY HOSPITAL HF156
Recruiting
Phase 3
Graft versus host disease prevention/reduction by microbiome and patient blood management in allogeneic hematopoietic stem cell transplant patientsCondition 1: graft versus host disease. Condition 2: acute graft versus host disease.Graft-versus-host diseaseAcute graft-versus-host diseaseD89.81D89.810
IRCT20190914044766N1High Institute for Research and Education in Transfusion Medicine40
Active, not recruiting
Phase 3
GRAPPA
2023-510441-24-00DKMS Group gGmbH640
Active, not recruiting
Phase 1
Prophylaxis of chronic graft-versus-host disease (cGvHD) with or without anti-thymocyte-globulin (ATG) prior allogeneic peripheral stem cell transplantation from HLA-identical siblings after myeloablative conditioning in patients with acute leukemia: a randomized phase III-study - NDAcute myeloid leukemia in first or subsequent complete remissionMedDRA version: 9.1Level: HLTClassification code 10024291Term: Leukaemias acute myeloid
EUCTR2005-005719-83-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI160